MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company’s European clinical trial evaluating the use of its SAMBATM Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
